Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,313
  • Shares Outstanding, K 23,080
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,060 K
  • 36-Month Beta 1.38
  • Price/Sales 165.25
  • Price/Cash Flow N/A
  • Price/Book 2.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.53 +16.99%
on 11/15/17
2.34 -23.50%
on 10/23/17
-0.52 (-22.51%)
since 10/20/17
3-Month
1.20 +49.17%
on 08/24/17
3.78 -52.65%
on 10/04/17
+0.58 (+47.93%)
since 08/22/17
52-Week
1.08 +65.74%
on 02/01/17
5.51 -67.51%
on 01/19/17
-2.21 (-55.25%)
since 11/22/16

Most Recent Stories

More News
Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview...

CATB : 1.79 (+2.87%)
Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation - Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catabasis Pharmaceuticals,...

MTG : 14.47 (-1.16%)
ARWR : 3.64 (+0.28%)
CATB : 1.79 (+2.87%)
LYV : 44.42 (+1.21%)
FLS : 39.49 (+1.28%)
SSNI : 16.19 (+0.19%)
Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress

-- Additional Preclinical Data Demonstrate Potential of CAT-5571 as a Treatment for Cystic Fibrosis; Plan to Initiate Phase 1 Trial in the Second Half of 2018 --

CATB : 1.79 (+2.87%)
Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM...

CATB : 1.79 (+2.87%)
Technical Insights on Biotech Stocks -- Cara Therapeutics, Catabasis Pharma, Cerus, and Genocea Biosciences

If you want a Stock Review on CARA, CATB, CERS, or GNCA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Friday, benchmark US indices were in bullish...

CARA : 12.19 (+1.16%)
CATB : 1.79 (+2.87%)
GNCA : 1.21 (+4.31%)
CERS : 3.74 (+0.81%)
Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2017 financial results after the NASDAQ Global Market close on...

CATB : 1.79 (+2.87%)
Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that CAT-5571, which restores host defense by activating autophagy, will...

CATB : 1.79 (+2.87%)
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy

Research Desk Line-up: XTL Biopharma Post Earnings Coverage

CATB : 1.79 (+2.87%)
XTLB : 2.42 (-1.22%)
Catabasis' DMD Candidate Slows Disease Progression, Stock Up

Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

PTCT : 15.84 (+0.32%)
CATB : 1.79 (+2.87%)
SRPT : 56.22 (+0.66%)
BIIB : 309.80 (+0.24%)
Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / U.S. markets continue to reach new record highs in the fourth quarter on strong economic data. The Dow Jones Industrial Average gained 0.09 percent to close...

CATB : 1.79 (+2.87%)
MNTA : 13.70 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 1.87
1st Resistance Point 1.83
Last Price 1.79
1st Support Level 1.74
2nd Support Level 1.69

See More

52-Week High 5.51
Fibonacci 61.8% 3.82
Fibonacci 50% 3.30
Fibonacci 38.2% 2.77
Last Price 1.79
52-Week Low 1.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart